scholarly journals Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Maha M. Eissa ◽  
Mervat Z. El-Azzouni ◽  
Labiba K. El-Khordagui ◽  
Amany Abdel Bary ◽  
Riham M. El-Moslemany ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Repurposing ◽  
Entrapment Efficiency ◽  
Effective Control ◽  
Fixed Dose ◽  
Electron Microscopic ◽  
Lipid Nanocapsules ◽  
Schistosomiasis Mansoni ◽  
Therapeutic Profile ◽  
Scanning Electron

Abstract Background The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal treatment. The aim of the present study was to utilize a novel combination of the three strategies to improve the therapeutic profile of praziquantel. This was based on a fixed-dose nanocombination of praziquantel and miltefosine, an antischistosomal repurposing candidate, co-loaded at reduced doses into lipid nanocapsules, for single dose oral therapy. Methods Two nanocombinations were prepared to provide 250 mg praziquantel-20 mg miltefosine/kg (higher fixed-dose) or 125 mg praziquantel-10 mg miltefosine/kg (lower fixed-dose), respectively. Their antischistosomal efficacy in comparison with a non-treated control and their praziquantel or miltefosine singly loaded counterparts was assessed in murine schistosomiasis mansoni. A single oral dose of either formulation was administered on the initial day of infection, and on days 21 and 42 post-infection. Scanning electron microscopic, parasitological, and histopathological studies were used for assessment. Preclinical data were subjected to analysis of variance and Tukeyʼs post-hoc test for pairwise comparisons. Results Lipid nanocapsules (~ 58 nm) showed high entrapment efficiency of both drugs (> 97%). Compared to singly loaded praziquantel-lipid nanocapsules, the higher nanocombination dose showed a significant increase in antischistosomal efficacy in terms of statistically significant decrease in mean worm burden, particularly against invasive and juvenile worms, and amelioration of hepatic granulomas (P ≤ 0.05). In addition, scanning electron microscopy examination showed extensive dorsal tegumental damage with noticeable deposition of nanostructures. Conclusions The therapeutic profile of praziquantel could be improved by a novel multiple approach integrating drug repurposing, combination therapy and nanotechnology. Multistage activity and amelioration of liver pathology could be achieved by a new praziquantel-miltefosine fixed-dose nanocombination providing 250 mg praziquantel-20 mg miltefosine/kg. To the best of our knowledge, this is the first report of a fixed-dose nano-based combinatorial therapy for schistosomiasis mansoni. Further studies are needed to document the nanocombination safety and explore its prophylactic activity and potential to hinder the onset of resistance to the drug components.

scholarly journals Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

2020 ◽  
Author(s):  
Maha Mohamed Eissa ◽  
Mervat El-Azzouni ◽  
Labiba Khalil El-Khordagui ◽  
Amany Abdel Bary ◽  
Riham Mohamed El-Moslemany ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Repurposing ◽  
Entrapment Efficiency ◽  
Effective Control ◽  
Fixed Dose ◽  
Electron Microscopic ◽  
Lipid Nanocapsules ◽  
Schistosomiasis Mansoni ◽  
Therapeutic Profile ◽  
Scanning Electron

Abstract Background: The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal treatment. The aim of the present study was to utilize a novel combination of the three strategies to improve the therapeutic profile of praziquantel. This was based on a fixed-dose nanocombination of praziquantel and miltefosine, an antischistosomal repurposing candidate, co-loaded at reduced doses into lipid nanocapsules, for single dose oral therapy.Methods: Two nanocombinations were prepared to provide 250 mg praziquantel-20 mg miltefosine/kg (higher fixed-dose) or 125 mg praziquantel-10 mg miltefosine/kg (lower fixed-dose), respectively. Their antischistosomal efficacy in comparison with a non-treated control and their praziquantel or miltefosine singly loaded counterparts was assessed in murine schistosomiasis mansoni. A single oral dose of either formulation was administered on the initial day of infection, and on days 21 and 42 post-infection. Scanning electron microscopic, parasitological, and histopathological studies were used for assessment. Preclinical data were subjected to analysis of variance and Tukeyʼs post-hoc test for pairwise comparisons.Results: Lipid nanocapsules (~58 nm) showed high entrapment efficiency of both drugs (> 97%). Compared to singly loaded praziquantel-lipid nanocapsules, the higher nanocombination dose showed a significant increase in antischistosomal efficacy in terms of statistically significant decrease in mean worm burden, particularly against invasive and juvenile worms, and amelioration of hepatic granulomas (P ≤ 0.05). In addition, scanning electron microscopy examination showed extensive dorsal tegumental damage with noticeable deposition of nanostructures.Conclusions: The therapeutic profile of praziquantel could be improved by a novel multiple approach integrating drug repurposing, combination therapy and nanotechnology. Multistage activity and amelioration of liver pathology could be achieved by a new praziquantel-miltefosine fixed-dose nanocombination providing 250 mg praziquantel-20 mg miltefosine/kg. To the best of our knowledge, this is the first report of a fixed-dose nano-based combinatorial therapy for schistosomiasis mansoni. Further studies are needed to document the nanocombination safety and explore its prophylactic activity and potential to hinder the onset of resistance to the drug components.

scholarly journals A single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

2020 ◽  
Author(s):  
Maha Mohamed Eissa ◽  
Mervat El-Azzouni ◽  
Labiba Khalil El-Khordagui ◽  
Amany Abdel Bary ◽  
Riham Mohamed El-Moslemany ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Repurposing ◽  
Effective Control ◽  
Fixed Dose ◽  
Electron Microscopic ◽  
Lipid Nanocapsules ◽  
Schistosomiasis Mansoni ◽  
Scanning Electron Microscopic ◽  
Therapeutic Profile ◽  
Scanning Electron

Abstract Background: The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal treatment. The aim of the present study was to utilize a novel combination of the three strategies to improve the therapeutic profile of praziquantel. This was based on a fixed dose nanocombination of praziquantel and miltefosine, an antischistosomal repurposing candidate, co-loaded at reduced doses into lipid nanocapsules, for single dose oral therapy.Methods: Two nanocombinations were prepared to provide 250 mg praziquantel-20 mg miltefosine/kg (higher fixed dose) or 125 mg praziquantel-10 mg miltefosine/kg (lower fixed dose) respectively. Their antischistosomal efficacy in comparison with nontreated control and their praziquantel or miltefosine singly loaded counterparts was assessed in murine schistosomiasis mansoni. A single oral dose of either formulation was administered on the initial day of infection, the 21st and 42nd days post infection. Scanning electron microscopic, parasitological and histopathological studies were used for assessment. Preclinical data were subjected to analysis of variance and Tukey post hoc test for pairwise comparisons.Results: Lipid nanocapsules (~58 nm) showed high entrapment efficiency of both drugs (>97%). Compared to singly loaded praziquantel-lipid nanocapsules, the higher dose nanocombination showed a significant increase in antischistosomal efficacy in terms of statistically significant decrease in mean worm burden, particularly against invasive and juvenile worms, and amelioration of hepatic granulomas (p ≤0.05). In addition, scanning electron microscopic examination showed extensive dorsal tegumental damage with noticeable deposition of nanostructures. Conclusions: The therapeutic profile of praziquantel could be improved by a novel multiple approach integrating drug repurposing, combination therapy and nanotechnology. Multistage activity and amelioration of liver pathology could be achieved by a new praziquantel-miltefosine fixed dose nanocombination providing 250 mg praziquantel-20 mg miltefosine/kg. To the best of our knowledge, this is the first report of a fixed dose nano-based combinatorial therapy for schistosomiasis mansoni. Further studies are needed to document the nanocombination safety and explore its prophylactic activity and potential to hinder the onset of resistance to the drug components.

scholarly journals A single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

2020 ◽  
Author(s):  
Maha Mohamed Eissa ◽  
Mervat El-Azzouni ◽  
Labiba Khalil El-Khordagui ◽  
Amany Abdel Bary ◽  
Riham Mohamed El-Moslemany ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Repurposing ◽  
Effective Control ◽  
Fixed Dose ◽  
Electron Microscopic ◽  
Lipid Nanocapsules ◽  
Schistosomiasis Mansoni ◽  
Scanning Electron Microscopic ◽  
Therapeutic Profile ◽  
Scanning Electron

Abstract Background: The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal treatment. The aim of the present study was to utilize a novel combination of the three strategies to improve the therapeutic profile of praziquantel. This was based on a fixed dose nanocombination of praziquantel and miltefosine, an antischistosomal repurposing candidate, co-loaded at reduced doses into lipid nanocapsules, for single dose oral therapy. Methods: Two nanocombinations were prepared to provide 250 mg praziquantel-20 mg miltefosine/kg (higher fixed dose) or 125 mg praziquantel-10 mg miltefosine/kg (lower fixed dose) respectively. Their antischistosomal efficacy in comparison with nontreated control and their praziquantel or miltefosine singly loaded counterparts was assessed in murine schistosomiasis mansoni. A single oral dose of either formulation was administered on the initial day of infection, the 21st and 42nd days post infection. Scanning electron microscopic, parasitological and histopathological studies were used for assessment. Preclinical data were subjected to analysis of variance and Tukey post hoc test for pairwise comparisons. Results: Lipid nanocapsules (~58 nm) showed high entrapment efficiency of both drugs (>97%). Compared to singly loaded praziquantel-lipid nanocapsules, the higher dose nanocombination showed a significant increase in antischistosomal efficacy in terms of statistically significant decrease in mean worm burden, particularly against invasive and juvenile worms, and amelioration of hepatic granulomas (p ≤0.05). In addition, scanning electron microscopic examination showed extensive dorsal tegumental damage with noticeable deposition of nanostructures. Conclusions: The therapeutic profile of praziquantel could be improved by a novel multiple approach integrating drug repurposing, combination therapy and nanotechnology. Multistage activity and amelioration of liver pathology could be achieved by a new praziquantel-miltefosine fixed dose nanocombination providing 250 mg praziquantel-20 mg miltefosine/kg. To the best of our knowledge, this is the first report of a fixed dose nano-based combinatorial therapy for schistosomiasis mansoni. Further studies are needed to document the nanocombination safety and explore its prophylactic activity and potential to hinder the onset of resistance to the drug components.

scholarly journals A single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

2020 ◽  
Author(s):  
Maha Mohamed Eissa ◽  
Mervat El-Azzouni ◽  
Labiba Khalil El-Khordagui ◽  
Amany Abdel Bary ◽  
Riham Mohamed El-Moslemany ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Drug Repurposing ◽  
Effective Control ◽  
Fixed Dose ◽  
Electron Microscopic ◽  
Lipid Nanocapsules ◽  
Schistosomiasis Mansoni ◽  
Histopathological Studies ◽  
Therapeutic Profile ◽  
Scanning Electron

Abstract Background: The control of schistosomiasis has been centered to date on a single drug, praziquantel (PZQ), with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal treatment. The aim of the present study was to utilize a novel combination of the three strategies to improve the therapeutic profile of PZQ. This was based on a fixed dose nanocombination of PZQ and miltefosine (MFS), an antischistosomal repurposing candidate, co-loaded at reduced doses into lipid nanocapsules (LNCs), for single dose oral therapy. Methods: Two nanocombinations were prepared to provide 250 mg PZQ-20 mg MFS/kg (higher fixed dose) or 125 mg PZQ-10 mg MFS/kg (lower fixed dose) respectively. Their antischistosomal efficacy in comparison with nontreated control and their PZQ or MFS singly loaded counterparts was assessed in murine schistosomiasis mansoni. A single oral dose of either formulation was administered on the initial day of infection, the 21 st and 42 nd days post infection. Scanning electron microscopic (SEM), parasitological and histopathological studies were used for assessment. Preclinical data were subjected to analysis of variance and Tukey post hoc test for pairwise comparisons. Results: Compared to singly loaded PZQ-LNCs, the higher dose nanocombination showed a significant increase in antischistosomal efficacy in terms of % reduction in worm burden, particularly against invasive and juvenile worms, and amelioration of hepatic granulomas. The efficacy of the higher dose nanocombination was significantly greater than that of its lower dose counterpart. SEM showed extensive dorsal tegumental damage with noticeable deposition of nanostructures. Conclusions: The therapeutic profile of PZQ could be improved by a novel multiple approach integrating drug repurposing, combination therapy and nanotechnology. Multistage activity and amelioration of liver pathology could be achieved by a new PZQ-MFS fixed dose nanocombination providing 250 mg PZQ-20 mg MFS/kg. To the best of our knowledge, this is the first report of a fixed dose nano-based combinatorial therapy for schistosomiasis mansoni. Further studies are needed to document the nanocombination safety and explore its prophylactic activity and potential to hinder the onset of resistance to the drug components. Key words: Praziquantel, miltefosine, lipid nanocapsules, Schistosoma mansoni, nanocombination, multistage activity, tegumental targeting, scanning electron microscopy

scholarly journals A single oral fixed - dose praziquantel-miltefosine nanocombination for effective control of experimental Schistosomiasis mansoni

2020 ◽  
Author(s):  
Maha Mohamed Eissa ◽  
Mervat El-Azzouni ◽  
Labiba Khalil El-Khordagui ◽  
Amany Abdel Bary ◽  
Riham Mohamed El-Moslemany ◽  
...  
Keyword(s):  
Electron Microscopy ◽  
Scanning Electron Microscopy ◽  
Combination Therapy ◽  
Schistosoma Mansoni ◽  
Drug Repurposing ◽  
Fixed Dose ◽  
Schistosomiasis Control ◽  
Lipid Nanocapsules ◽  
Therapeutic Profile ◽  
Scanning Electron

Abstract Background: Schistosomiasis control has been centered to date on praziquantel, with shortcomings involving ineffectiveness against immature worms, reinfection and emergence of drug resistance. Strategies based on drug repurposing and/or praziquantel combination therapy proved effective, though with some limitations. Combining such strategies with nanotechnology would further augment therapeutic benefits. Nanocarrier-mediated delivery of multiple drugs in schistosomiasis control has not been documented to date. Our objective was to combine drug repurposing, combinational therapy and nanotechnology for the development of a single oral fixed dose nanocombination to improve praziquantel therapeutic profile. This was based on praziquantel and an antischistosomal repurposing candidate miltefosine, co-loaded into lipid nanocapsules in reduced doses. Methods: Two fixed dose lipid nanocapsule formulations were prepared at two concentration levels of praziquantel and miltefosine. Their antischistosomal activity in comparison with control singly loaded lipoid nanocapsules was assessed in Schistosoma mansoni- infected mice. Single oral dos of 250mg praziquantel-20mg miltefosine/kg and 125mg praziquantel-10mg miltefosine/kg were administered on the initial day of infection, 21st and 42nd days post infection. Scanning electron microscopy, parasitological and histopathological studies were used for assessment. In vivo data were subjected to analysis of variance and post hoc test (Tukey) was used for pairwise comparisons. Results: Lipid nanocapsules showed a mean diameter of 58 nm and high entrapment efficiency of both drugs (>95%). Compared to singly loaded lipid nanocapsules, the larger dose praziquantel-miltefosine nanocombination exerted high antischistosomal efficacy in terms of % reduction of worm burden, particularly when given against invasive and juvenile worms, and amelioration of hepatic granulomas. Scanning electron microscopy revealed extensive tegumental damage with noticeable deposition of nanostructures. Conclusions: A fixed dose praziquantel-miltefosine nanocombination offers great potential as a novel single dose oral antischistosomal therapy offering multistage activity and protection against hepatic pathology. The novel drug repurposing/combination therapy/nanotechnology multiple approach has the potentials of improving the therapeutic profile of praziquantel, achieving radical cure, hindering resistance to the component drugs, and simplifying praziquantel chemotherapy. Key words: Praziquantel, miltefosine, lipid nanocapsules, Schistosoma mansoni, nanocombination, multistage activity, tegumental targeting, scanning electron microscopy. ​ [LE1] [LE1]

Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni

Acta Tropica ◽  
2016 ◽  
Vol 159 ◽  
pp. 142-148 ◽  
Author(s):  
Riham M. El-Moslemany ◽  
Maha M. Eissa ◽  
Alyaa A. Ramadan ◽  
Labiba K. El-Khordagui ◽  
Mervat Z. El-Azzouni
Keyword(s):  
Single Dose ◽  
Oral Treatment ◽  
Drug Repurposing ◽  
Lipid Nanocapsules ◽  
Schistosomiasis Mansoni ◽  
Dose Oral

Stavudine Loaded Microcapsules using various Cellulose Polymers: Preparation and In-Vitro Evaluation

2009 ◽  
Vol 2 (2) ◽  
pp. 551-556
Author(s):  
Narayana R. Padala ◽  
Prakash K. ◽  
C. S. Reddy Bonepally ◽  
Krishnaveni B. ◽  
Shantakumari K. ◽  
...  
Keyword(s):  
Release Kinetics ◽  
Liquid Paraffin ◽  
Methyl Cellulose ◽  
Entrapment Efficiency ◽  
In Vitro Dissolution ◽  
Scanning Calorimetry ◽  
Electron Microscopic ◽  
Accelerated Stability ◽  
Scanning Electron

The objective of the present study was to prepare and characterize the microcapsules for the controlled release of Stavudine using cellulose acetate butyrate (CAB), ethyl cellulose (EC), hydroxy propyl methyl cellulose phthalate (HPMCP). The microcapsules were prepared by solvent evaporation method using acetone and liquid paraffin as a drug dispersion and liquid manufacturing phase, respectively. The prepared microcapsules were characterized for particle size distribution (PSD), percent drug content, entrapment efficiency, Fourier Transform Infrared Spectroscopy (FTIR), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and in vitro dissolution studies. The prepared microcapsules were filled in hard gelatin capsules and kept for accelerated stability study as per ICH guidelines for about 3 months. The prepared microcapsules were spherical and free flowing. The entrapment efficiency was found to be 25-45%. The release of drug from the microcapsules was extended upto 12 hours and more. FTIR and DSC thermo graphs showed stable character of stavudine. Scanning electron microscopic study revealed that then microcapsules were spherical and porous in nature. The release kinetics study revealed that the prepared microcapsules were best fitted to the Higuchi model, first order and followed by Zero order and indicating that the drug release was diffusion controlled. The release was mainly influenced by the type of polymer and its viscosity. The DSC study revealed that there is no drug to polymer interaction and showed the stable character of the drug which was further confirmed by the assay of accelerated stability of microcapsules.

Scanning Electron Microscopic Study of the Cell Surface

1969 ◽  
Vol 27 ◽  
pp. 36-37 ◽  
Author(s):  
Toichiro Kuwabara
Keyword(s):  
Tissue Fluid ◽  
Biological Application ◽  
Biological Structure ◽  
Electron Microscopic ◽  
Surface Appearance ◽  
Minute Amount ◽  
Scanning Electron Microscopic Study ◽  
Scanning Electron Microscopic ◽  
True Structure ◽  
Scanning Electron

Although scanning electron microscopy has a great potential in biological application, there are certain limitations in visualization of the biological structure. Satisfactory techniques to demonstrate natural surfaces of the tissue and the cell have been reported by several investigators. However, it is commonly found that the surface cell membrane is covered with a minute amount of mucin, secretory substance or tissue fluid as physiological, pathological or artefactual condition. These substances give a false surface appearance, especially when the tissue is fixed with strong fixatives. It seems important to remove these coating substances from the surface of the cell for demonstration of the true structure.

A scanning electron microscopic study on dissolving process of cholesterol gallstones by chenodeoxycholic acid (CDCA)

1978 ◽  
Vol 36 (2) ◽  
pp. 522-523
Author(s):  
T. Kanetaka ◽  
M. Cho ◽  
S. Kawamura ◽  
T. Sado ◽  
K. Hara
Keyword(s):  
Electron Microscope ◽  
Chenodeoxycholic Acid ◽  
Outer Surface ◽  
Electron Microscopic ◽  
Cholesterol Gallstones ◽  
The Core ◽  
Scanning Electron Microscopic Study ◽  
Scanning Electron Microscopic ◽  
Acceleration Voltage ◽  
Scanning Electron

The authors have investigated the dissolution process of human cholesterol gallstones using a scanning electron microscope(SEM). This study was carried out by comparing control gallstones incubated in beagle bile with gallstones obtained from patients who were treated with chenodeoxycholic acid(CDCA).The cholesterol gallstones for this study were obtained from 14 patients. Three control patients were treated without CDCA and eleven patients were treated with CDCA 300-600 mg/day for periods ranging from four to twenty five months. It was confirmed through chemical analysis that these gallstones contained more than 80% cholesterol in both the outer surface and the core.The specimen were obtained from the outer surface and the core of the gallstones. Each specimen was attached to alminum sheet and coated with carbon to 100Å thickness. The SEM observation was made by Hitachi S-550 with 20 kV acceleration voltage and with 60-20, 000X magnification.

A Comparative Study of Fractographic Replicas

1974 ◽  
Vol 32 ◽  
pp. 566-567
Author(s):  
Loren Anderson ◽  
Pat Pizzo ◽  
Glen Haydon
Keyword(s):  
Electron Microscopy ◽  
Electron Microscopic Examination ◽  
Direct Examination ◽  
Electron Microscopic ◽  
Reliable Technique ◽  
Service Failures ◽  
Transmission Electron ◽  
Mode Of Failure ◽  
Scanning Electron Microscopic ◽  
Scanning Electron

Transmission electron microscopy of replicas has long been used to study the fracture surfaces of components which fail in service. Recently, the scanning electron microscope (SEM) has gained popularity because it allows direct examination of the fracture surface. However, the somewhat lower resolution of the SEM coupled with a restriction on the sample size has served to limit the use of this instrument in investigating in-service failures. It is the intent of this paper to show that scanning electron microscopic examination of conventional negative replicas can be a convenient and reliable technique for determining mode of failure.

Sign in / Sign up

Export Citation Format

Share Document